Harmony Biosciences to Present at the Oppenheimer Rare and Orphan Disease Summit
Harmony Biosciences Holdings, based in Plymouth Meeting, PA, announced a company update presentation at the Oppenheimer Rare and Orphan Disease Summit on May 21, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harmony Biosciences Holdings, based in Plymouth Meeting, PA, announced a company update presentation at the Oppenheimer Rare and Orphan Disease Summit on May 21, 2021. President and CEO John C. Jacobs and Chief Medical Officer Dr. Jeffrey Dayno will host investor meetings during the event. The presentation will be accessible via a webcast on Harmony's investor page. The company focuses on developing therapies for rare neurological disorders with unmet medical needs.
Details
News Market Reaction – HRMY
The recorded move for HRMY in the trading session of this news was +0.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that Harmony's President and CEO, John C. Jacobs and Chief Medical Officer, Dr. Jeffrey Dayno will present a company update and host investor meetings at the Oppenheimer Rare and Orphan Disease Summit on Friday, May 21, 2021.
A webcast of the presentation will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, with a vision to provide novel treatment options for people living with rare neurological disorders who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.
Harmony Biosciences Investor Contact:
Lisa Caperelli
484-539-9736
lcaperelli@harmonybiosciences.com
Harmony Biosciences Media Contact:
Nancy Leone
215-891-6046
nleone@harmonybiosciences.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/harmony-biosciences-to-present-at-the-oppenheimer-rare-and-orphan-disease-summit-301293012.html
SOURCE Harmony Biosciences
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.